Similar articles

• OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.

  Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR Jr. Woodle ES, et al. Clin Transplant. 1996 Aug;10(4):389-95. Clin Transplant. 1996. PMID: 8884115
• OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.

  Cinti P, Cocciolo P, Evangelista B, Orlandini AM, Bruzzone P, Renna Molajoni E, Cortesini R. Cinti P, et al. Transplant Proc. 1996 Dec;28(6):3214-6. Transplant Proc. 1996. PMID: 8962245 Clinical Trial. No abstract available.
• Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.

  Piatosa B, Grenda R, Prokurat S. Piatosa B, et al. Transplant Proc. 1996 Dec;28(6):3466-7. Transplant Proc. 1996. PMID: 8962349 Clinical Trial. No abstract available.
• Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.

  Colvin RB, Preffer FI. Colvin RB, et al. Clin Lab Med. 1991 Sep;11(3):693-714. Clin Lab Med. 1991. PMID: 1934971 Review.
• Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.

  Goldstein G. Goldstein G. Transplant Proc. 1987 Apr;19(2 Suppl 1):1-6. Transplant Proc. 1987. PMID: 3105134 Review. No abstract available.